CardieX Limited (ASX: CDX) is a company which belongs to the healthcare industry and into the business of development and marketing of the AtCor Medical’s SphygmoCor device, announced that the study on SphygmoCor technology revealed that it could monitor the central blood pressure and has an improved prediction of cardiovascular events as compared to the standard peripheral pressure. The SphygmoCor technology is used for assessing and managing the cardiovascular patient. AtCor Medical is a subsidiary company of CardieX Limited.[optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
The study on the SphygmoCor technology was conducted and published by the Clinical and Experimental Hypertension Journal. It was led by the Shanghai Jiatong School of Medicine in China and collaboration with the Department of Hypertension and the Department of Geriatrics at the Ruijin Hospital North (an affiliate hospital of SOM), together with Australia’s Department of Biomedical Sciences at Macquarie University.
AtCor’s SphygmoCor technology is used to analyze the central arterial pressure waveform for the management of blood pressure. Through this system, the physicians would be able to customize care for patients with hypertension, renal disease, COPD, diabetes, and heart failure among other diseases and conditions. The SphygmoCor technology’s central blood pressure waveform analysis enables a better way of managing patients by managing the central pressures and treat the patents as per the guidelines of the central blood pressure.
The study was also performed to access the prediction of cardiovascular events in a hypertensive cohort through the SphygmoCor technology. The technology was also used to perform noninvasive measurements of central aortic BP, brachial BP, wave reflection, augmentation index, pressure amplification, and pulse wave velocity on 675 patients diagnosed with hypertension with an average follow-up period of 25 months.
The data based on the study shows that central systolic blood pressure (cSBP) and central pulse pressure (cPP) has a higher hazard ratio for cardiovascular events as compared to the peripheral pressure counterparts at the age of 60 and above. The study also proved that the monitoring of the central blood pressure improved the prediction of cardiovascular events compared to peripheral pressure for patients who are 60 and above during the follow-up of almost two years. Based on the study outcome, there was a requirement for the CardieX’s SphygmoCor system as it demonstrates its superiority in predicting the future risk of cardiovascular event.
At present, AtCor’s SphygmoCor technology is used across 20 hospitals on the U.S. News Best Hospitals 2017-2018 Honor Roll. It has also received support from various pharmaceutical companies across the world who are trying to investigate and also validate the effects of novel drugs on heart vascular interactions.
CardieX is looking forward to crucial OEM licensing and product strategy initiatives in China in 2019 headed by ZiHan Lin(VP of Corporate Development) and Lawrence Chan (Director of Product Development and Technology).
Since the inception of CDX, the stock has generated a negative performance of 65.82%. However, since last one year, the stock gave a positive return of 63.37%.
With the market open on 4 February 2019, the opening price of the stock was A$0.054. At present, the shares of CDX are trading at A$0.050 (3:15 pm AEST, 4 February 2019) which is down by 7.41% with the market capitalization of A$34.08 million with approximately 631. 15 million outstanding shares.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.